Clinical Trial Update: Safety and Efficacy Study of LUM001 in the Treatment of Cholestatic Liver Disease in Patients With Alagille Syndrome [Phase 2]

View source ↗

Summary

Phase 2 clinical trial assessing safety and efficacy of LUM001 for cholestatic liver disease in Alagille Syndrome has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alagille Syndrome

Drugs mentioned

• LUM001

Snippet

Sponsor: Mirum Pharmaceuticals, Inc. | Conditions: Alagille Syndrome | Phase 2 | Status: COMPLETED | Results posted: 2015-12-07